Curriculum Vitae

NAME:	**Susan Jane Steen, M.D.**
MEDICAL LICENSE NUMBER:	ME0035639
DATE OF BIRTH:	[redacted]
PLACE OF BIRTH:	Philadelphia, Pennsylvania
ADDRESS (RES):	[redacted]
ADDRESS (BUS):	Tampa Neurology Associates 2919 Swann Avenue, Suite 401 Tampa, Florida 33609
MARITAL STATUS:	Married to Dominick Joseph Graziano One daughter, one son
EDUCATION:	
1970 - 1974	Bachelor of Science, Magna Cum Laude Florida State University Tallahassee, Florida
1974 - 1978	Doctor of Medicine University of Florida Gainesville, Florida
1978 - 1980	Resident, Internal Medicine University of South Florida and Affiliated Hospitals Tampa, Florida
1980 - 1983	Resident, Neurology University of Florida Gainesville, Florida
CURRENT POSITION:	Private Practice, Neurology, 1983- to date Tampa Neurology Associates 2919 Swann Avenue, Suite 401 Tampa, Florida 33609 President, Axiom Clinical Research of Florida 2919 Swann Avenue, Suite 105A Tampa, FL 33609
PUBLICATIONS:	"Oxacillin and Hepatitis", Annals of Internal Medicine, May 1979 (letter)

LICENSURES/BOARD CERTIFICATION:
State of Florida, 1978, #35639
National Boards, Medicine & Surgery, 1979
National Boards, Neurology and Psychiatry, 1991

ORGANIZATIONS:
American Academy of Neurology
American Medical Association
Hillsborough County Medical Association
Florida Medical Association
American Women's Medical Association
Alzheimer's Association Gulf Coast Chapter, Board Member 2018
Women Physicians of Hillsborough County
Athena Society, Member 2006
Women of Influence, Member 2006
Life Path Hospice, Physician Advisory Board, 2015

HOSPITAL STAFF:
Memorial Hospital of Tampa (Stroke Director)
Tampa General Hospital
Arden Courts of Tampa – Physician Advisor
Estate Senior Living ALF – (Physician Advisor)

AWARDS/ACADEMIC SOCIETIES:

1971	Mortar Board
1971	Phi Kappa Phi
1971	Alpha Lambda Delta
1974	Phi Beta Kappa
1978	Outstanding Senior Medical Student in Neurology
2000	American Headache Society (AHS)

CERTIFICATION:
Expert Medical Advisor, Orientation & CEUs
Bureau of Rehabilitation & Medical Services (Division of Workers' Compensation) - 02/21/98

DRUG STUDIES:
Cognex Access Program: A Treatment Indicate Program for Patients with Alzheimer's Disease.
July 1993

Parke-Davis
Protocol 970-58

DRUG STUDIES
(CONTINUED):

A Natural History Study of Patients with Amyotrophic Lateral Sclerosis using the Tufts Quantitative Neuro-muscular Exam.
September 1993

Syntex-Synergen
Protocol 604a
Investigator

A Double-Blind, Parallel, Placebo-Controlled, Multiple Dose, 6-Month Study Assessing the Safety & Efficacy of Daily Subcutaneous Injections of Recombinant Human Ciliary Neurotrophic Factor [rhCNTF] in patients with Amyotrophic Lateral Sclerosis [ALS].

Syntex-Synergen
Protocol 604b
Investigator

Rh CNTF for the Treatment of Amyotrophic Lateral Sclerosis.

Syntex-Synergen
September 1993
Protocol 606
Investigator

A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Two Dose Levels (10 mg., and 20 mg.) of Intranasal Sumatriptan in the Acute Treatment of a Migraine Attack.

Glaxo Pharmaceuticals
Protocol S2B-340
Investigator

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Headache Pain Relief with Sumatriptan Nasal Spray [5 mg, 10 mg. & 20 mg] across three migraine attacks.

Sumatriptan [Glaxo]
Protocol S2b-342
Investigator

DRUG STUDIES (CONTINUED):

A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Two Dose Levels (10 mg. and 20 mg.) of Intranasal Sumatriptan in the Acute Treatment of a Migraine Attack.

Glaxo Pharmaceuticals
Investigator

Landmark Investigation of Felbamate in Epilepsy (L.I.F.E.) A 7-Week Open Label Replacement Therapy Protocol in Patients with Partial Epilepsy.
January 1994

Sabeluzole (R58-735) - Clinical Evaluation of Efficacy and Safety of Sabeluzole in the Treatment of Alzheimer's disease.

Investigator

Clinical Evaluation of Extended-Release Oral Physostigmine in the Treatment of Patients with Dementia of the Alzheimer's Type (PR 1028).
November 1994

Forest Laboratories
Investigator

A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effectiveness and Safety of MigramistJ (Dihydroergotamine Mesylate Nasal Spray) 2 mg for the Acute Treatment of Migraine Headache with or without Aura in Migraineur Families.
February 1995

Sandoz Pharmaceuticals
Principal Investigator

A Trial of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF) Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis (ALS).

Amgen-Regeneron Partners
Protocol 930121
Investigator

DRUG STUDIES
(CONTINUED):

An Active Treatment Safety Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF) Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis (ALS).

Amgen-Regeneron Partners
Protocol 960116
Investigator

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of the Safety and Efficacy of Intravenous Activase7 Alteplase, Recombinant (Recombinant Tissue Plasminogen Activator, rt-PA) within 3-5 Hours of Onset of Acute Ischemic Stroke.

Genentech, Inc
Protocol A0276g
Investigator

An Open-Label, Multicenter Clinical Trial Evaluating the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Alzheimer's Disease.

Eisai America, Inc
Protocol E2020-A001-313
Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Sumatriptan Injection on Workplace Productivity Loss Due to Migraine.

Glaxo Wellcome, Inc.
Protocol SUMA4015
Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Tolerability of Four Doses of Oral Naratriptan in the Acute Treatment of a Single Migraine Attack.

Glaxo Pharmaceuticals
Protocol S2WA3001
Investigator

DRUG STUDIES (CONTINUED):

A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety and Efficacy of Oral Naratriptan in the Acute Treatment of Four Migraine Attacks.

Glaxo Pharmaceuticals
Protocol S2WA3003
Investigator

A Phase 2/3 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of Intravenous Aptiganel Hydrochloride versus Placebo in Patients with an Acute Ischemic Stroke.

Boehringer Ingelheim Pharmaceuticals, Inc
Protocol 534.11
Investigator

An Open, Randomized, Multicenter Study to Assess the Efficacy and Safety of 1.25 mg. QD and 10 mg. QD Zydis Selegiline in the Control of Symptoms of Parkinson's Disease in Patients Stabilized on a Regimen Including Selegiline.

Scherer DDS
Protocol Z/SEL/95/008
Investigator

An Open, Multicenter Parallel Group Continuation Study To Assess The Safety Of 1.25 mg q.d. and 10 mg. Q.D. Zydis Selegiline in the Control of Symptoms of Parkinson's Disease in Patients stabilized on a regimen including Selegiline.

Scherer DDS/Harris Clinical Research
Protocol Z/SEL/95/008/Extension
Investigator

A Multicenter, Double-blind, Randomized Comparison of Zolmitriptan and Sumatriptan in the Acute Treatment of Multiple Migraine Headaches.

Zeneca
Protocol 311C90
Principal Investigator

DRUG STUDIES (CONTINUED):

A Double-Blind Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan Succinate Table (25 or 50 mg) in the Acute Treatment of Migraine.

Glaxo Wellcome, Inc
Protocol SUMA4014
Principal Investigator

A Treatment Protocol Using Myotrophin (human mecasermin [recombinant DNA origin]) Injection in Patients With Amyotrophic Lateral Sclerosis.

Cephalon, Inc
Protocol C0151a/500/AL/US (version1,3)
Investigator

A 26-week Prospective, Multi-Center, Open Label, Randomized, Study to Compare Metrifonate and Standard Care. Patients With Dementia of the Alzheimer's Type of Mild to Moderate Severity Will Be Assigned to One of Two Treatment Arms (Metrifonate or Standard Care; 4:1 randomization.)

Bayer Pharmaceutical
M.I.N.T.
Bay a 9826
Principal Investigator

The Effects of 2,000 mg Citicoline on Clinical Outcome and Evolution of Lesion Volume in Human Stroke.

Interneuron Pharmaceuticals Inc.
Protocol IP302-018
Investigator

A Randomized Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5 mg q.d with Placebo as an Adjunct in the Management of Parkinsonian Patients Being Treated With Levodopa Who Exhibit Deterioration in the Quality of Their Response to This Therapy.

Scherer DDS/MDS Harris
Protocol #Z/SEL/97/026
Investigator

DRUG STUDIES (CONTINUED):

Clinical Experience and use of Sabril (Vigabatrin) in Patients with Partial Seizures.

Hoechst Marion Roussel, Inc.
Protocol Number VGPR0098
Clinical Phase IIIb
Investigator

A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Stratified, Parallel-Group Trial of Rufinamide as Adjunctive Therapy in Children and Adults With Inadequately Controlled Partial Seizures.

Novartis
Phase III - Final Clinical Trial Protocol #3310101021
CGP33101 (Rufinamide)
Investigator

A Double-Blind, Placebo-Controlled, Safety, Efficacy and Dose Response Trial in Three Intravenous Doses of BMS-204352 in Patients with Acute Stroke.

Bristol-Myers-Squibb
Phase II - Clinical Protocol # CN123-011
Principal Investigator

A Double-Blind, Placebo-Controlled, Safety, Efficacy and Dose Response Trial of Three Intravenous Doses of BMS-204352 in Patients with Acute Stroke.

Bristol-Myers Squibb
BMS-204352 Stroke Study CN 123-011-039
Principal Investigator

An Open Extension Study of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5 mg q.d. as an Adjunct in the Management of Parkinsonian Patients being reated with Levodopa.

Scherer DDS
Protocol Z/SEL/97/027
Investigator

DRUG STUDIES (CONTINUED):

A One Year Open Label Safety Study of ZanaflexR (Tizanidine HCL) In The Treatment of Spasticity Associated With Chronic Stroke.

Athena Neurosciences Inc.
AN021-452
Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate A1T-082 in Patients with Probable Alzheimer's Disease of Mild to Moderate Severity (90 day treatment period plus 60 days follow-up).

NeoTherapeutics Inc.
082-99-003
Principal Investigator

An Open Label Dose Titration Safety and Efficacy Study of ZanaflexR (Tizanidine HCL) In The Treatment of Spasticity Associated with Chronic Stroke.

Athena Neurosciences Inc
AN021-450
Investigator

A Registry of Arrhythmias in Myotonic Muscular Dystrophy.

Indiana University
04-01-98
Investigator

Pregabalin BID, An Open-Label Multicenter Follow-On Study to Determine Long Term Safety and Efficacy in Patient with Partial Seizures.

Park-Davis Pharmaceutical Research
Protocol 1008-035-070
Principal Investigator

Lamictal, In Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.

Glaxo-Wellcome
Protocol LM40091
Investigator

DRUG STUDIES (CONTINUED):

A Prospective, Randomized, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Iloperidone Compared with Risperidone (both 0.5 to 4.0 mg/d given b.i.d.) In Treating Psychotic and Behavioral Symptoms in Institutionalized Elderly Patients with Dementia.

Novartis
Principal Investigator

A Double-Blind, Placebo-Controlled Study of Depakote in the Treatment of Behavioral Agitation in Elderly Patients with Dementia.

Abbott Laboratories
Protocol M99-082
Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo - Controlled Flexible Dose Study of Ariprprazole in the Treatment of Institutionalized Patients with Psychosis Associated with dementia of the Alzheimers Type.

Bristol-Myers Squibb (BMS) and Otsuka America Pharmaceutical (OAPI).
Protocol CN138-005
Principal Investigator

ECLIPSE Exploring CompLIance, Packaging, and SafEty
A Compliance, Packaging and Safety Assesssment of Two Packaging Formats and Dosing Regimens of GABITRIL (tiagabine hydrocholoride) in Subjects with Partial-Onset Seizures.

Abbott Laboratories
Protocol M00-190
Principal Investigator

An Open-label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) In Female Subjects with Newly Diagnosed Epilepsy Initiating Anti-Epileptic Drug Treatment on either Lamotrigine or Valproate Monotherepy

Glaxo Wellcome, INC
Protocol LAM30007
Principal Investigator

DRUG STUDIES (CONTINUED):

The Betaseron Experience Satisfaction Trial (Best) in Educated Multiple Sclerosis Patients BEST trial

Investigator

Efficacy and Safety of a flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of

Alzheimers Disease.
Janssen Research Foundation
Protocol RIS-USA-232
Principal Investigator

A Randomized, Open-Label, Parallel-Groups, Outpatient Study to Examine the Long-Term Safety and Tolerability of Rizatriptan 5 mg P.O. for the Acute Treatment of Migraine in Adolescents.

Merck & CO.
Protocol 061-00
Principal Investigator

A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial and an Open Label Long Term Tolerability Trial of Zolmitriptan (Zomig) for the Acute Treatment of Migraine Headaches in Adolescent subjects.

AstraZeneca
Protocol 311CUS/0005/0058
Principal Investigator
September 2001

A Randomized, 30-Week, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Dementia Secondary to Cerebrovascular Disease.

Janssen
Protocol GAL-INT-26
Principal Investigator
August 2001

DRUG STUDIES (CONTINUED):

A Multicenter, Phase IV, Randomized, Open-Label Study to Compare the Efficacy of Two Therapies (Acetaminophen and Prednisone) in the Management of Flu-like Symptoms Associated with Avonex (Interferon beta 1a) Treatment in Patients with Relapsing Multiple Sclerosos (AIMS)

Protocol C-858
Principal Investigator
April 2001

A Multicenter, Randomized, Open-Label Comparison of the Effects of ZOMIG-ZMT (zolmitriptan) and Usual Migraine Care on Work Loss, Productivity, and Patient Preference.

Protocol 311CUS/0016
Investigator
September 2001

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of ONO-2506 Intravenous Infusion on the Amelioration of Neurological Damage and Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic Stroke.

ONO
Protocol ONO 2506/INT0104
Principal Investigator

Clopidrogel for High Atherothrombotic Risk and Stabilization, Management and Avoidance (CHARISMA).

Sanofi-Synthelabo/Bristol-Myers Squibb
Protocol CV 149009
Principal Investigator

A Multi-Center, Double-Blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated with Dementia.

AstraZeneca
Protocol 5077US/0046

DRUG STUDIES (CONTINUED):

A Phase-II, Randomized, Double-Blind, Placebo-Controlled, Escalating Dose Study of the Safety and Tolerability of SUN N4057 Administered for 72 Hours by Continuous Intravenous Infusion in Successive Cohorts of Patients with Acute Ischemic Stroke.

Suntory Pharmaceuticals
Protocol SPI-102
Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Middle of the Night Administration of NBI034060 in Patients with Primary Insomnia.

Neurocrine Biosciences
Protocol NBI-34060-IR-0209
Principal Investigator

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated Dementia of the Alzheimer's Type.

Bristol Myers Squibb
Protocol CB-138-005-036
Principal Investigator

A Phase-II, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of SNK-860 in Subjects with Diabetic Neuropathy.

Sanwa Kagaku Kankyusho Co., Ltd.
Protocol AR-USA-01
Investigator

BioBank Repository: Collection of Blood, Plasma, and Leukocytes with Matching Demographic, Clinical and Medical History.

Seracare Life Sciences.
Protocol 2467
Investigator

DRUG STUDIES (CONTINUED):

A Phase-II Trial to Evaluate the Nutritioinal Properties of the Herbal Dietary Supplement QR-334 for Subjects with Excessive Salivary Secretions.

Quigley Pharmaceuticals.
Protocol QR-334-001
Investigator

A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Leg Syndrome (RLS).

GSK
Protocol 101468/249
Principal Investigator

International, Randomized, Multi-Center, Phase-III Study in Patients with Relapsing-Remitting Multiple Sclerosis Comparing over a Treatment Period of 104 weeks: Double-Blinded the Safety and Efficacy of Betaseron/Betaferon 250 g (8 MIU) and Betaseron/Betaferon 500 g (16 MIU), Both Given Subcutaneously Every Other Day; Rater-blinded the Safety, Tolerability, and Efficacy of Betaseron/Betaferon s.c. Every Other Day with Copaxone 20 mg. s.c. Once Daily.

Berlex Laboratories
Protocol 306440
Investigator

DNA/RNA/Serum Banking in Subjects with Late Onset Alzheimer's Disease.

PrecisionMed
Protocol 1007
Principal Investigator

DNA/RNA/Serum Banking in Subjects with Early Onset Alzheimer's Disease.

PrecisionMed
Protocol 1010
Principal Investigator

DRUG STUDIES (CONTINUED):

A Phase-III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adult Subjects with Chronic Insomnia.

Takeda
Protocol 01-02-TL-375-020
Principal Investigator

A Phase-III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects with Chronic Insomnia.

Takeda
Protocol 01-02-TL-375-022
Principal Investigator

A Phase-II, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Subjects with Chronic Insomnia.

Takeda
Protocol 01-02-TL-375-025
Principal Investigator

A Phase-II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose CAMPATH (MABCAMPATH) and High-Dose Rebif in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis.

Ilex Pharmaceuticals
Protocol CAMMS223
Investigator

A Phase-III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanirole versus Placebo in Patients with Early Parkinson's Disease.

Pharmacia
Protocol DA2APD-0075-031

DRUG STUDIES (CONTINUED):

A Randomized, Rater-Blinded, Multi-Center, Parallel-Group Study Comparing the Efficacy and Safety of Betaseron 250 g Subcutaneously Every Other Day with Avonex 30 g Intramuscularly Once Per Week in Relapsing/Remitting Multiple Sclerosis Patients Previously Treated with Avonex.

Berlex Laboratories
Protocol 307245
Investigator

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA).

Sanofi-Synthelabo Research, USA
Protocol EFC4505
Principal Investigator

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine.

AstraZeneca
Protocol 311CUS/0022
Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Comparison of the Effect of ONO-2506 Intravenous Infusion on the Amelioration of Neurological Damage and Improvement in Stroke Assessment Scale Scores in Subjects with Acute Ischemic Stroke.

ONO Pharmaceuticals
Protocol 2506/INT0104
Principal Investigator

A Multi-Center, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200 mg/day, 300 mg/day, and 400 mg/day compared with Placebo in Subjects with Painful Diabetic Neuropathy.

Glaxo-SmithKline
Protocol NPP30005
Investigator

DRUG STUDIES (CONTINUED):

A Randomized, 30-Week, Double-Blind, Placebo-Controlled, Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Dementia Secondary to Cerebrovascular Disease.

Johnson & Johnson Research Foundation
Protocol GAL-INT-26/22
Principal Investigator

A Phase-III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-35060 in Adult Primary Insomnia Patient with Sleep Maintenance Difficulties.

PPD Development
Protocol NBI-34060-MR-0404
Principal Investigator

A 5-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of [s,s] – Reboxetine in Patients with Postherpetic Neuralgia (PNN), who are Gabapentin Treatment Failures.

Pfizer
Protocol A6061001
Principal Investigator

A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults with Primary Progressive Multiple Sclerosis.

Genentech, Inc.
Protocol U2786g
Investigator

A Multi-Center, Double-Blind, Randomized, Parallel-Group Evaluation of Lamictal Extended-Release Adjunctive Therapy in Subjects with Partial Seizures.

Glaxo-Smith Kline
Protocol LAM100034
Investigator

DRUG STUDIES (CONTINUED):

A Double-Blind, Placebo-Controlled, Parallel-Group Study, with an Open-Label Extension Phase, to Assess the Efficacy, Tolerability & Safety of Oral Frovatriptan in the Prevention of Menstrually-Related Migraine (MRM) Headaches in a "Difficult to Treat" Population.

Vernalis Development, Ltd.
Protocol VML-251-3MRM02
Principal Investigator

A 12-Week, Double-Blind, Placebo-Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Leg Syndrome (RLS) Requiring Extended Treatment Coverage.

Glaxo-Smith Kline
Protocol 100013
Principal Investigator

A Phase III Study of the Safety and Efficacy of Alzheimer in Patients with the Mild-to-Moderate Alzheimer's Disease.

Neurochem, Inc.
Protocol CL-758007
Principal Investigator

Phase-III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type.

Myriad Pharmaceuticals, Inc.
Protocol MPC-7869-04-005.02
Principal Investigator

A Double-Blind, Phase II, Safety and Efficacy Evaluation of ONO-2506POU in Patients with Mild to Moderate Alzheimer's Disease.

ONO Pharm. USA, Inc.
Protocol ONO-2506POU010
Principal Investigator

DRUG STUDIES (CONTINUED):

An Assessment of Behavioral Changes Associated with Lamotrigine & Levetiracetam in Patients with Epilepsy

Glaxo-Smith Kline
Protocol LAM40124
Investigator

A Phase IV, 2-Year, Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole versus Ropinirole in Early Parkinson's Disease.

Boehringer Ingelheim Pharmaceuticals, Inc.
Protocol 248.538
Principal Investigator

A Phase IV, 12-Week, Multicenter, Open Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients with Mild to Moderate Alzheimer's Disease.

Eisai/Pfizer
Principal Investigator

Effectiveness and Safety of Frovatriptan for the Management (Acute Treatment) of Menstrual Migraines – Phase IV.

Endo Pharmaceuticals
Protocol EN3266-401
Investigator

A Phase III, Randomized, Controlled Comparison of Nefiracetam with Placebo in the Treatment of Patients with Post-Stroke Apathy.

Hamilton Pharmaceuticals, Inc.
Protocol HPI-001-01
Principal Investigator

A Phase III, 4-Week, Randomized, Double Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Leg Syndrome (RLS).

GlaxoSmithKline
Protocol ROX104805
Principal Investigator

DRUG STUDIES (CONTINUED):

A Phase III, 52-Week, Open Label Study to Assess the Long Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS).

GlaxoSmithKline
Protocol ROX101468/206
Principal Investigator

Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response (INSIGHT)

Biogen Idec
Protocol 008-05-AVX

A Multi-Site, Open Clinical Study to Collect Biological Specimens and Phenotypic Data from a Large Cohort of Subjects for Inclusion in a Repository and Use in Genomic (from DNA and RNA), Serologic and Metabolic (from serum) and Proteomic (from protein research studies).

Genomics Collaborative
Protocol C 101-216
Investigator

A Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter, Outpatient Study to Assess the Efficacy and Safety of Doxepin HCl in Elderly Patients with Primary Sleep Maintenance Insomnia.

Somaxon Pharmaceuticals
Protocol SP-0509
Investigator

A Phase II, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients with Restless Leg Syndrome (RLS).

Xenoport, Inc.
Protocol XP-052
Principal Investigator

A Phase II, Randomized, Open Label, Three-Arm Study Comparing Low and High Dose CAMPATH (MABCAMPATH) and High Dose Rebif in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis.

Genzyme Corporation
Protocol CAMMS223-A6
Investigator

DRUG STUDIES (CONTINUED):

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% in Patients with Pain from Carpal Tunnel Syndrome.

Endo Pharmaceuticals
Protocol EN3272-301
Investigator

Effect of Septal Closure of Atrial PFO on Events of Migraine with Premere: ESCAPE Migraine Trial.

St. Jude Medical, Inc.
Protocol IDE #G050112
Investigator

A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects who Report Poor Response or Intolerance to Eletriptan.

GlaxoSmithKline
Protocol TRX106571
Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients with Mild to Moderate Alzheimer's Disease.

Memory Pharmaceuticals Corporation
Protocol MEM 1003-004
Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of MK-0859 in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Merck & Company
Protocol MK-0859-003
Investigator

DRUG STUDIES
(CONTINUED):

A Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment.

Cognition Pharmaceuticals, Inc.
Protocol 22029
Investigator

An Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer's Type.

Myriad Pharmaceuticals, Inc.
Protocol MPC-7869-05-009
Principal Investigator

A Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type.

Myriad Pharmaceuticals, Inc.
Protocol MPC-786905-010
Principal Investigator

An Open Label Extension of the Phase III Study CL-758007 with Alzheimer in Patients with Alzheimer's Disease

Neurochem, Inc.
Protocol CL-758017
Principal Investigator

A 24-Month, Double-Blind, Randomized, Multicenter, Placebo-Controlled Parallel Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis.

Novartis Pharmaceuticals Corporation
Protocol CFTY720D-2309
Investigator

DRUG STUDIES
(CONTINUED):

A 12-Month, Double-Blind, Randomized, Multicenter, Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily versus Interferon B-1a (Avonex) Administered I.M. Once Weekly in Patients with Relapsing-Remitting Multiple Sclerosis with Optional Extension Phase.

Novartis Pharmaceuticals Corporation
Protocol CFTY720D-2302
Investigator

A Phase-II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of Add-On Cladribine Tablet Therapy with Rebif New Formulation in MS Subjects with Active Disease

Serono, Inc
Protocol 26593
Investigator

A Randomized, Multicenter, Two-Arm, Open Label, 12-Week Phase III-B Study to Evaluate the Tolerability of Rebif (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-Naive Subjects with Relapsing-Remitting Multiple Sclerosis, Followed by a Single Arm 24-week, Rebif-Only Safety Extension.

Serono, Inc.
Protocol 27133
Investigator

A Randomized, Controlled, Open Label, Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing, Antibody Testing on Treatment Patterns versus Usual Care in High Dose Interferon Treated Subjects.

Teva Neuroscience, Inc.
Protocol Nabs PM028
Investigator

DRUG STUDIES (CONTINUED):

An Open Labeled, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients with Restless Legs Syndrome.

XenoPort, Inc.
Protocol XP055
Principal investigator

A Randomized, Double-Blind, Placebo-Controlled Dose Response Study to Assess the Efficacy, Safety and Pharmacokinetics of XP13512 in Patients with Restless Legs Syndrome.

XenoPort, Inc.
Protocol XP081
Principal Investigator

A Phase-II, Open Label, Efficacy and Safety Study in Patients with Restless Legs Syndrome (RLS).

XenoPort, Inc.
Protocol XP-052
Principal Investigator

A Phase-III, Randomized, Double-Blind, Safety and Efficacy of Lidocaine Patch 5% in Patients with Carpal Tunnel Syndrome.

ENDO Pharmaceuticals
Protocol EN 3272-301
Investigator

Open Label Extension Safety and Efficacy Study in Patients with Restless Leg Syndrome.

Xenoport, Inc.
Protocol XP-055
Principal Investigator

A Phase-II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Efficacy and Pharmacokinetics Study in Patients with Restless Legs Syndrome (RLS).

Xenoport, Inc.
Protocol XP-081
Principal Investigator

DRUG STUDIES (CONTINUED):

A Phase-II, Safety, Tolerability and Efficacy Study of Add-on Orally Administered Medication in Multiple Sclerosis Patients with Active Disease.

Serono, Inc.
Protocol 26593
Investigator

A Phase-III-B, International, Multicenter, Open Label Relapsing-Remitting Multiple Sclerosis Clinical Trial.

Bayer, Inc.
Protocol 309363
Investigator

A Phase-III, Relapsing-Remitting Multiple Sclerosis Clinical Trial.

Genzyme Corporation
Protocol CAMMS 323
Investigator

An Open Label, Randomized, Multicenter, Parallel Group Study in Patients with Probable Alzheimer's Disease.

Novartis Pharmaceuticals
Protocol CENA 713 D US 38
Principal Investigator

A Randomized, Double-Blind, Parallel Group Study in Adult Patients with Chronic Insomnia.

Takeda Global Research & Development Center, Inc.
Protocol TAK 01-05-TL-375-069
Investigator

A Phase III, Randomized, Rater and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low and High Dose Alemguzumab to Three Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who have Relapsed on Therapy.

Genzyme Corporation
Protocol Number: CAMMS32400507
Investigator

DRUG STUDIES (CONTINUED):

A Phase III, Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment Naïve Patients with Relapsing-Remitting Multiple Sclerosis (CARE-MS I)

Genzyme Corporation
Protocol Number: CAMMS323
Investigator

A Phase III, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN 115727) in Patients with Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E e4 Non-Carriers

Elan Pharmaceuticals
Protocol Number: ELN05727-301
Principal Investigator

A Phase III, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN 115717) in Patients With Mild to Moderate Alzheimer's Disease Who Are Apolioprotein E e4 Carriers

Elan Pharmaceuticals
Protocol Number: ELN05727-302
Principal Investigator

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Outpatient Trial of PD 02003390 in Adults with Primary Insomnia

Pfizer, Inc.
Protocol Number: A4251037
Principal Investigator

A Randomized, Double Blind, Placebo-Controlled Trial of (S, S)-Reboxetine in Patients with Chronic Painful Diabetic Peripheral Neuropathy

Pfizer, Inc.
Protocol Number: A6061037
Investigator

DRUG STUDIES (CONTINUED):

A Phase IIA, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of T-817AMa in Patients with Mild to Moderate Alzheimer's Disease

Toyama Pharmaceuticals
Protocol Number: AA4437420
Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extensions to 26/52 Weeks

MAP Pharmaceuticals
Protocol Number: MAP0004-CL-P301
Investigator

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Novartis Pharmaceuticals, Inc.
Protocol Number: CFTY720D 2306
Investigator

Effect of LY450139, a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared with Placebo

Eli Lilly & Company
Protocol Number: H6L-MC-LFBC
Principal Investigator

Effect of LY2062430, on Anti-Amyloid Beta Monocolonal Antibody, on the Progression of Alzheimer's Disease as Compared with Placebo

Eli Lilly & Company
Protocol Number: H8A-MC-LZAM
Principal Investigator

DRUG STUDIES (CONTINUED):

A Phase II, Double-Blind, Randomized, Multicenter, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients with Relapsing-Remitting Multiple Sclerosis

Novartis Pharmaceuticals, Inc.
Protocol Number: CBAF312A2201
Investigator

A 14-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis.

Sanofi-Aventis
Protocol Number: DRI10566
Investigator

A Phase III Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, EKN115727) in Subjects with Alzheimer's Disease Who Participated in ELN115727-301 or in ELN115727-302

Janssen Alzheimer's Immunotherapy
Protocol Number: ELN115727-351
Principal Investigator

An Open Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase III Double-Blind Studies (H6L-MC-LFAN or H6L-MS-LFBC)

Eli Lilly & Company
Protocol Number: H6N-MC-LFBF
Principal Investigator

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Genzyme Corporation
Protocol Number: CAMMS03409
Investigator

DRUG STUDIES (CONTINUED):

A Phase-1-b Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients with Secondary Progressive Multiple Sclerosis or Relapsing Remitting Multiple Sclerosis

Elan Pharmaceuticals, Inc.
Protocol Number: ELND002-MS103
Investigator

A Twelve-Week Phase-III-b Open Label, Single Arm, Multicenter Trial to Evaluate Ease of Use of a Ready to Use Single Use Autoinjector (SA) for Self Injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated wit Rebif 44 mcg Subcutaneously (SC) Three Times a Week (TIW)

EMD Serono
Protocol Number: 29651
Investigator

A Twelve-Week Phase-III-b Open Label, Single Arm, Multicenter Trial to Evaluate Ease of Use of An Electronic Autoinjector (RebiSmart) for Self Injection in Subjects with Relapsing Multiple Sclerosis (RMS) Treated with Rebif 44 mcg Subcutaneously (SC) Three Times a Week (TIW)

EMD Serono
Protocol Number: 29652
Investigator

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2

Biogen Idec
Protocol Number: 101JC402
Investigator

A Multicenter, Randomized, Rater-Blinded, Parallel Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon B-1a to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis

Biogen Idec
Protocol Number: 101MS325
Investigator

DRUG STUDIES (CONTINUED):

Assessment of LY451395 for Neurophsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease

Eli Lilly & Company
Protocol Number: H6N-MC-LEAQ
Principal Investigator

A Ph III Multicenter Randomized Double Blind Double Dummy Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relappsing Multiple Sclerosis Patients

Receptos, Inc.
Protocol RPC01-301 (Sunbeam)
2014 – 2017
Sub-Investigator

Impact of the BETACONNECT Auto-Injector on BETASERON Therapy Adherence and Patient Satisfaction

Bayer HealthCare Pharmaceuticals
Protocol BETACONNECT
2018
Sub-Investigator

An Open Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects with Relapsing Remitting Multiple Sclerosis

Biogen Idec Research Limited
Protocol 109MS310
2018
Sub-Investigator

A Phase III Multicenter Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Biogen Idec Research Limited
Protocol 221AD302 (EMERGE/CLARITY)
2018
Principal Investigator

DRUG STUDIES (CONTINUED):

A Long Term Follow Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study
CAMMS03409

Genzyme / Sanofi Group
Protocol LPS13649 (TOPAZ)
2016 – PRESENT
Sub-Investigator

An Open Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerossis Who Have Had A Suboptimal Response to An Adequate Course of Disease-Modifying Treatment

Genentech, Inc.
Protocol MN30035
2019
Sub-Investigator

A Phase III Multicenter Randomized Double Blind Placebo Controlled Parallel Group Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease

F. Hoffmann-LaRoche Ltd
Protocol BN29552
2019
Principal Investigator

Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study

American College of Radiology Imaging Network
Protocol IDEAS
2018
Principal Investigator

A Randomized Double Blind Placebo Controlled Ph II Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Neurotrope BioScience
Protocol NTRP101-202
2016 – 2017
Principal Investigator

DRUG STUDIES (CONTINUED):

A Ph II A Randomized Parallel Group Placebo Controlled Study of 50 mg and 100 mg of SUVN-502 and Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride

Suven Life Sciences Ltd
Protocol CTP2S1502HT6 (SUVN-502)
2019
Principal Investigator

A Multicenter Randomized Placebo Controlled Double Blind 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Lovodop Induced Dyskinesias

BioRasi/Osmotica Pharmaceutical Corp
Protocol OS320-3006
2016—2016
Sub-Investigator

A Multicenter Randomized Placebo Controled Double Blind 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa Induced Dyskinesias

BioRasi/Osmotica Pharmaceutical Corp
Protocol OS320-3005
2016—2016
Sub-Investigator

A Ph IIb Double Blind Randomized Placebo Controlled Study of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)

Axovant Sciences Ltd
Protocol RVT 101-2001
2018
Principal Investigator

A Long Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Lewy Bodies (DLB)

Axovant Sciences Ltd
Protocol RVT 101-2002
2018
Principal Investigator

A 24 Months Ph III Multicenter Placebo Controlled Study of

Efficacy and Safety of Solanezumab vs Placebo in Prodromal Alzheimer's Disease

Eli Lilly & Company
Protocol H8A-MC-LZBE
2016—2017
Principal Investigator

A Multicenter Randomized Parallel Group 78 Weeks Long Double Blind Placebo Controlled Study of 2 Fixed Dose Levels of LY3314814 in Patients with Mild Alzheimer's Disease and Abnormal Levels of Amyloid Followed by a 78 Weeks Long Delayed Start Period

Eli Lilly & Company
Protocol 18D-MC-AZET (Daybreak)
2018
Principal Investigator

Effect of LY3202626 on Alzheimer's Disease Progression As Measured by Cerebral 18F-AV-1451 Tau-Pet in Mild Alzeimer's Disease Dementia

Eli Lilly & Company
Protocol 17X-MC-LLCF
2018
Principal Investigator

A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis

Novartis Pharmacueticals
Protocol COMB157G2302 (Asclepios)
2016—Present
Sub-Investigator

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Avid Radiopharmaceuticals, Inc.
Protocol 18F-AV-45-A25 (RAmp)
2018
Principal Investigator

A Multi-Site Open Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Receptos, Inc.
Protocol RPC01-3001
2019

Sub-Investigator

DRUG STUDIES (CONTINUED):

An Open Label Extension Study of the Effects of Leuco-methylthioninium bis (hydromethansulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia

Tau Rx Therapeutics Ltd
Protocol TRx-237-020
2018
Principal Investigator

A Multi-Center Screening Study With Flortaucipir F18 in patient with early symptomatic AD

Principal Investigator

ADVANCE: Addressing Dementia via Agitation-Centered Evaluation. A Randomized Double-Blind, Placebo-Controlled Trial to Assess the Efficacy & Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's type.

Principal Investigator

A Phase-II, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients with Probable Alzheimer's Disease

Protocol: NPT088-CL002
Principal Investigator

A Two-year, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability and the Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis.

Protocol: EFC11759/Terikdis
Sub-Investigator

A Phase-II, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy & Safety of one Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Post-Traumatic Headache (PPTH).

Protocol: TV48125-CNS-20024
Sub-Investigator

Assessment of Safety, Tolerability, and Efficacy of

LY3002813 in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company
Protocol 15T-MC-AACG
2017-2019
Principle Investigator

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease

Biogen Pharmaceuticals
Protocol 251AD201
2018- Present
Principle Investigator

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease

F. Hoffman La Roche
Protocol WN39658
2019- Present
Principle Investigator

Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated with Idiopathic Parkinson's Disease (PD) or Dementia with Lewy Bodies (DLB)

Eli Lilly and Company
Protocol 17S-MC-HBEH
2019-Present
Principle Investigator

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Episodic Migraine

Allergan Pharmaceuticals International
Protocol 3101-301-002
2019- Present
Principle Investigator

Allergan Atogepant 3101-309-002 Open Label Extension

Allergan Pharmaceuticals International
Protocol 3109-301-002
2019- Present
Principle Investigator

Exploring the Safety and Tolerability of Conversion from Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients with Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multicenter Phase IIIb Study

Novartis Pharmaceuticals
Protocol CBAF312AUS02
2018- Present
Sub-Investigator

An Open-Label, Single-Arm, Multi-Center Extension Study Evaluating Long-Term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects with Relapsing Multiple Sclerosis

Novartis Pharmaceuticals
Protocol COMB157G2399
2019-Present
Sub-Investigator

A Prospective, Multicenter, Observational, Post-Authorization Safety Study to Evaluate the Long-Term Safety Profile of Lemtrada (alemtuzumab) Treatment in Patients with Relapsing Forms of Multiple Sclerosis

Sanofi
Protocol OBS13434
2018-Present
Sub-Investigator
A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment

Adamas Pharmaceuticals
Protocol ADS-AMT-MS303
2019- Present
Sub-Investigator

HOSPITAL & OTHER APPOINTMENTS:

Tampa General Hospital
October 1988 to September 1991
Member, Executive Committee

Tampa General Hospital
October 1988 to October 1994
Professional Credentials Committee

Memorial Hospital
December 1992 to December 1994
Special Care Committee

Memorial Hospital
November 1996 to November 1998
Chief, Department of Medicine

Memorial Hospital
December 1995 to December 2002
Member, Executive Committee

Memorial Hospital
December 1998 to December 2000
Board of Governors Representative

Memorial Hospital
December 1998 to December 2000
Chief, Medical Staff

Memorial Hospital
June 1997 to 2007
Medical Director, Memory Disorder Clinic

Memorial Hospital of Tampa
Stroke Director
June 2005 – Present

South Tampa Memory Center
Medical Director, 2007-Present

Alpha House of Tampa, Board Member
2003- Present
Board President - December 2006 - December 2008

American Heart Association
Community Board Member, 2005-2009

HOSPITAL & OTHER APPOINTMENTS:

National Founding Member “Learn & Live Society”

Chairperson, Circle of Red
Go Red for Women Luncheon, 2004 – 2009

Judeo Christian Clinic, Physician Volunteer
1995-Present

Humana National Advisory Board Member
February 2009 – Current

Arden Court, Medical Advisor
May 2010 - Present

Other: Local and National Speaker for Companies including Abbott, Astra Zeneca, Acadia, Allergan, Avanir, Boehringer Ingelheim, Eisai, Forest, Glaxo-Wellcome-Celinex, Janssen, Lilly, Merck, Novartis, Ortho-McNeil, Parke-Davis, Pfizer, Teva Pharmaceuticals, UCB

Horizon Bay Memory Center, The Estate
Medical Advisor
2012 – Present

Life Spring Home Health Physician Advisor
2017 - Present

PRIZES & AWARDS: Award bestowed by Epilepsy Foundation, “The Barbara McNerney Award for Outstanding Services” to Neurology Associates, P.A.
November 19, 1993

SIGNATURE: _____

UPDATE: **August, 2019**